Validation of a questionnaire measuring patient knowledge of atrial fibrillation in an Asian cohort
Conclusions
A questionnaire on the knowledge of AF and its treatment was validated in a cohort of Asian patients in English and Mandarin. It allows quantification of patient knowledge and may be useful in Asian populations to assess the efficacy of interventions to improve patient understanding of AF. (Source: Heart Asia)
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Hoe, R., Lin, W., Bautista, M. A. C., Vrijhoef, H. J. M., Lim, T. W. Tags: Original research Source Type: research
Author index
Au Timmy WK, A10 Cally HO, A10 Casida Jesus M, A3, A9 Chan Cecilia MC, A3 Chan David, A13 Chan Joseph YS, A13 Chan Kai Man, A11 Cheung Lily, A5 Chow Josie, A13 Fan Katherine, A11 Fan Yiting, A13 Fung Erik, A2, A11, A13 Graham Colin A, A6 Jiang Jiangang, A7 Kam Kevin KH, A2, A13 Karthikeyan Ganesan, A12 Katherine FAN, A10 Kerk Ka Lee, A10 Kiernan Michael S, A6, A9 Kim Jung-Hwan, A8 Lee Alex PW, A2, A13 Lee Jenny SW, A5 Li Sheng, A7 Lo Raymond SK, (Source: Heart Asia)
Source: Heart Asia - April 24, 2019 Category: Cardiology Tags: Author Index Source Type: research
33 Hypertrophic cardiomyopathy: pathogenesis, therapies and disease modulation
Hypertrophic cardiomyopathy (HCM) is a prevalent heritable cardiac disorder, characterised by unexplained left ventricular hypertrophy (LVH) with the triad of myocyte hypertrophy, disarray, and interstitial fibrosis.1 Such pathological hallmarks impact diastolic function and contribute to adverse clinical outcomes: arrhythmias, progressive heart failure and sudden cardiac death.2 To date, none of the available armamentaria has been shown to fundamentally modify disease progression, or to benefit genotype-positive, phenotype-negative or preclinical HCM patients. Multiple genetic studies have identified considerable numbers ...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Teekakirikul, P. Tags: Keynote Lecture Source Type: research
32 Epidemiology of heart failure in south asia
South Asia has seen rapid epidemiological transition in the last two decades with a rapid rise in cardiovascular diseases, which have emerged as the leading cause of mortality in this region. In India the leading cause of disability adjusted life years is ischaemic heart disease which has seen a 104% increase between 1990 and 2016.1 Similarly the burden of obesity, hypertension and diabetes mellitus has increased markedly over this time and with poor control rates for these risk factors leading to a fertile soil for rise in incidence of heart failure.2 In the absence of active surveillance mechanisms reliable estimates of ...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Roy, A. Tags: Keynote Lecture Source Type: research
31 Fabry disease in east asia
Fabry disease (FD) is an X-linked inherited lysosomal storage disorder that results from mutations in the α-galactosidase A gene (GLA), leading to deficient alpha-galactosidase A (α-GalA) activity and subsequent accumulation of globotriaosylceramide (Gb3) in a variety of tissues.1 The estimated prevalence of classic FD in males ranges from 1:8000 to 1:117,000,2 likely an underestimation given its non-specific manifestations. The mutation IVS4 +919G>A (c.936+919G>A) associated with founder effect in East Asia was first described in Taiwan.3Left ventricular hypertrophy (LVH) is a hallmark of the later-onset...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Lee, A. P., Kam, K. K., Fung, E., Chow, J., Fan, Y., Teekakirikul, P., Wong, K., Chan, J. Y., Chan, D., Sheng, B. Tags: Keynote Lecture Source Type: research
30 Advances in medical and interventional treatments for CTEPH
Pulmonary endarterectomy is the standard care for patients with chronic thromboembolic pulmonary hypertension (CTEPH), however, about 40% of them are inoperable. Several controlled and uncontrolled trials have shown that the use of pulmonary arterial hypertension (PAH)-specific drugs might be useful in inoperable CTEPH.1 2 Riociguat is currently the only PAH-specific drug also approved for inoperable CTEPH.3
Recently, balloon pulmonary angioplasty (BPA) has emerged as an alternative treatment option for patients with inoperable CTEPH or persistent PH after surgery. Several reports now support the efficacy and safety of BP...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Taniguchi, Y. Tags: Keynote Lecture Source Type: research
29 Management of pulmonary hypertension in systemic lupus erythematosus patients
Pulmonary arterial hypertension (PAH) is a complex and devastating disease. According to a longitudinal United States-based registry, connective tissue disease (CTD) accounted for more than 50% of all patients with PAH, in which systemic sclerosis comprised the largest CTD-related PAH.1 In contrast to Western countries, systemic lupus erythematosus (SLE) is a more common CTD than systemic sclerosis in the Asia-Pacific region.2 A cohort study from China has shown that SLE, instead of systemic sclerosis, comprised the largest proportion of all CTD-related PAH.3 The prevalence of PAH in SLE is estimated at 0.5%–17.5%.4 ...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Wong, P. C. Tags: Keynote Lecture Source Type: research
28 Should we be using digoxin in 2018?
Digoxin is often used in the management of patients with heart failure (HF) with or without atrial fibrillation (AF). There is sound biological rationale for the use of digoxin, but the data on clinical outcomes with digoxin use in this patient population are conflicting. There is a single adequately powered randomised trial of digoxin in patients with HF in sinus rhythm.1 This trial showed a small but significant reduction in the rate of hospitalisation due to HF with the use of digoxin, when compared to placebo, among patients treated with ACE inhibitors and diuretics. There was no effect on mortality.1 On the contrary, ...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Karthikeyan, G. Tags: Keynote Lecture Source Type: research
27 Lower limb ischaemia in patients undergoing VA ECMO
The incidence of lower limb ischaemia ranges from 11%–52% in patients receiving VA ECMO. The reported rate of amputation ranges from 2%–10%. Patients with vascular complications related to lower limb ischaemia carries a higher risk of death. Antegrade perfusion of superficial femoral artery via a distal perfusion catheter (DPC) has been shown to be an effective therapy to reduce the incidence of lower limb ischaemia. However, the clinical indications remain largely unclear with various reported strategies. While the benefits remain largely unknown, there is increasing experience on the use of near-infrared refl...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Chan, K. M. Tags: Keynote Lecture Source Type: research
26 CardiomemsTM in VAD patients
Successive generations of left ventricular assist devices (LVADs) have been associated with improvement in patient outcomes and reduction in device-related complications.1 Beyond mortality reduction, quality of life improvement and reduction in hospitalisation are increasingly focused upon. Following LVAD implantation, the number of admissions per year is highest in the first year.2 3 In fact, within 30–90 days, hospitalisation for volume overload – indicative of acute worsening heart failure, haemodynamically significant arrhythmias or imbalance of haemodynamics due to suboptimal LVAD pump settings – cou...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Fung, E. Tags: Keynote Lecture Source Type: research
25 Malignancy after heart transplantation
In the current era, approximately 50% of heart transplant (HTx) recipients survive more than 13 years, with an increasing population of patients surviving beyond 20 years. Previous studies have suggested that HTx recipients are at particularly high risk of developing de novo malignancies due to more intensive immunosuppression. The perception of higher risk for post-transplant lymphoproliferative disease (PTLD; e.g. lymphoma) associated with OKT3 led to a fall in the use of OKT3 during the 1990s. Main advances in post-HTx management with probable reduction of risk for neoplasia are introduction of (1) antiviral prophylaxis...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Fan, K. Tags: Keynote Lecture Source Type: research
24 Managing infections associated with LVADs
Although left ventricular assist devices (LVADs) have revolutionised the treatment of advanced heart failure, LVAD infection (LVADI) remains a significant cause of morbidity and mortality in LVAD patients.
The International Society of Heart and Lung Transplantation defines LVADI in three categories: VAD-specific infections (pump/cannula, pocket, driveline); VAD-related infections (infective endocarditis, blood stream infection, mediastinitis); and non-VAD infections.1
Infection should be excluded or appropriately treated by an infectious disease physician before LVAD implantation when clinically feasible. Surgical techniq...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Kerk, K. L. Tags: Keynote Lecture Source Type: research
23 Stroke outcomes in patients with left ventricular assist device
In conclusion, stroke remains an important cause of morbidity and mortality among Hong Kong patients receiving LVAD therapy. (Source: Heart Asia)
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Wong, K., Cally, H., Au, T. W., Katherine, F. Tags: Keynote Lecture Source Type: research
22 Renal complications in LVAD and heart transplant patients
Renal dysfunction remains a primary determinant of both short- and long-term outcomes following heart transplantation (HTx) and ventricular assist device (VAD) implantation.1 2 Challenging to the assessment of candidacy for advanced heart failure (HF) therapies is the ability to distinguish intrinsic parenchymal renal disease from reversible cardiorenal disease. Patients with haemodynamically mediated renal failure may recover kidney function once renal perfusion is restored following HTx or VAD surgery. Chronic hypoperfusion, however, can lead to progressive structural lesions that may not improve despite correction of un...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Kiernan, M. S. Tags: Keynote Lecture Source Type: research
21 Surgical care and perioperative nursing management of LVADs
Discussion of the nursing management of patients post-LVAD implant in the critical care, progressive care, and in the outpatient care settings will be approached at conceptual level. This approach will equip the participant with a ‘thinking framework’ guiding his/her actions in caring for LVAD patients. Salient nursing actions include early detection and management of post-surgical complications, device-related complications, heart failure symptom exacerbations, infection, among others. The nurse’s role in helping patients attain an optimum level of functioning post-implantation during hospitalisation and...
Source: Heart Asia - April 24, 2019 Category: Cardiology Authors: Casida, J. M. Tags: Keynote Lecture Source Type: research
